The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

A generic latanaprost solution from Gland Pharma has received FDA approval for the treatment of open angle glaucoma and ocular hypertension.

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

Nocturnal intraocular pressure (IOP) profiling has shown that the peak IOP usually occurs at night, particularly in patients with glaucoma. Multiple studies have demonstrated that these ...

The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes. While studies of obesity and tobacco ...

Potential subjects were excluded if they had had previous glaucoma surgery or laser and also if intraocular surgery or additional SLT procedures were performed after the first treatment.

University of California, San Diego-led research suggests that long-term variability in blood pressure is associated with accelerated worsening of peripheral vision due to the progression of glaucoma.

Anchor] Macular degeneration is a disease in which vision decreases due to abnormalities in the macula, the center of the ...